GCM
GILD icon

Gabalex Capital Management’s Gilead Sciences GILD Stock Holding History

Gabalex Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-225,000
Closed -$16.1M – 19
2016
Q4 		$16.1M Sell
225,000
-50,000
-18% -$3.72M 5.44% 11
2016
Q3 		$21.8M Buy
275,000
+25,000
+10% +$2.03M 7.62% 4
2016
Q2 		$20.9M Buy
250,000
+25,000
+11% +$2.22M 7.6% 7
2016
Q1 		$20.7M Buy
225,000
+75,000
+50% +$6.76M 7.16% 5
2015
Q4 		$15.2M Buy
150,000
+50,000
+50% +$5.2M 5.84% 8
2015
Q3 		$9.82M Buy
+100,000
New +$11.1M 3.82% 12

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Gabalex Capital Management's GILD Position: Q1 2017 in Review

Gabalex Capital Management sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 225,000 shares — an estimated $16.1M sold.

Gabalex Capital Management first reported a position in GILD in Q3 2015 and held it in 6 quarters. The position peaked at $21.8M in Q3 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Gabalex Capital Management reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Gabalex Capital Management sold 225,000 Gilead Sciences shares in Q1 2017, an estimated $16.1M.
  • Gabalex Capital Management first reported a position in Gilead Sciences in Q3 2015 and held it in 6 quarters.
  • Gabalex Capital Management's Gilead Sciences position peaked at $21.8M in Q3 2016.
  • 1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Gabalex Capital Management's 13F filing for Q1 2017, filed 3 May 2017.